DOCSLIB.ORG

ROBERT M. CALIFF PAGE 1 Of

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ROBERT M. CALIFF PAGE 1 Of DUKE UNIVERSITY MEDICAL CENTER CURRICULUM VITAE Name: Robert McKinnon Califf, M.D., M.A.C.C. Primary academic appointment: Vice Chancellor for Clinical Research Present academic rank and title: Vice Chancellor for Clinical Research Duke University Medical Center Director, Duke Translational Medicine Institute Professor of Medicine, Division of Cardiology Donald F. Fortin Professor, Cardiology Medical licensure: North Carolina License # 26208 Specialty certification: American Board of Internal Medicine 1984 Cardiovascular Diseases 1986 Fellow, American College of Cardiology 1988 Education: Institution Year Degree College: Duke University 1973 BS, Psychology Graduate/ Duke University 1978 MD Professional School Training: University of California, San Francisco 1978 - 1979 Intern, Medicine University of California, San Francisco 1979 - 1980 Assistant Resident, Medicine Duke University Medical Center 1980 - 1983 Fellow, Cardiology Faculty appointments: Associate in Medicine 1982 - 1983 Duke University Medical Center Assistant Professor of Medicine 1983 - 1989 Duke University Medical Center Associate Professor of Medicine 1989 - 1995 Duke University Medical Center Director, Duke Clinical Research Institute 1995 - 2006 Duke University Medical Center Professor of Medicine 1995 - Present Associate Vice Chancellor for Clinical Research 1995 - 2006 Vice Chancellor for Clinical Research 2006 - Present Director, Duke Translational Medicine Institute 2006 - Present PAGE 1 of 114 ROBERT M. CALIFF Duke positions held: Director, CCU 1982 - 1994 Medical Officer – Life Flight 1984 - 1990 Executive Committee of the Medical Staff, Member 1995 - Chair, Committee on Health Information Policy & Services 1995 - 2007 Executive Committee, Duke Medicine (School and Health System) 1995 - Strategy Committee, Duke Health System 1995 - 2004 Chair, Clinical Sciences Faculty Council 1996 - 1998 University Patent Policy Committee 2002 - 2008 Academic Council Trustee Nomination Committee 2002 - 2005 Executive Committee for the Development of the Personalized Health Plan 2003 - 2006 Executive Management Committee of the Health System, Duke University School of Medicine, Member 2004 - Department of Medicine Advisory Board - Senior Advisor 2003 - 2006 University Intellectual Property Board 2003 - 2006 Chancellor’s Academic Cabinet, Member 2005 - Chair – Quality Metrics Committee – Duke Health Systems 2005 - 2006 Academic Leadership Council 2005 - Duke School of Medicine Executive Compliance Committee 2007 - Duke School of Medicine Strategic Funds Committee 2007 - Y.T. and Alice Chen Pediatric Genetics & Genomics Research Center Scientific Advisory Board 2007 - present Duke Heart Center Executive Leadership Committee 2008 - 2010 Co-Chair, Durham Health Innovations Oversight Committee 2008 – David H. Murdock Research Institute, Board Member 2008 Clinical Research Redesign Committee 2009 Professional positions: American Board of Medical Specialties 1999 - American College of Cardiology- Fellow (F.A.C.C) 1988 – 2006 Chair, Merck Fellowship Awards Committee 1990 – 1996 Board of Trustees 2000 - 2005 Task Force on Science and Quality of Care 2000 - 2002 Board of Trustees Working Group on Compensation 2002 - 2004 Annual Self Assessment 2002 - 2003 Quality Strategic Oversight Committee 2002 – 2008 Task Force on Work Force 2003 - 2004 AHA/ Consensus Conference on Ethics 2003 – Quality Strategic Directions Committee 2005 - 2008 Master (M.A.C.C.) 2006 - Young Investigators Award Committee 2006 - 2009 Awards Committee 2007 - 2009 American Heart Association Council on Clinical Cardiology 1995 – Scientific Publishing Committee 2006 -2008 American Heart Journal – Editor-in-Chief 1996 - Donald W Reynolds Foundation Cardiovascular Research Advisory 1997 - 2009 Doris Duke-Scientific Advisory Committee 1998 - 2004 FDA Cardio-Renal Advisory Committee 1996 - 2000 FDA Science Board Working Group 2007 - 2008 National Cancer Inst. Implementation Committee on Clinical Trials 1997 - 1998 National Heart, Lung, and Blood Institute Working Group on Clinical Research 1998 - 2000 Coordinating Center for Education and Research on– PAGE 2 of 114 ROBERT M. CALIFF Therapeutics (CERTs) – PI 1999 – 2007 Center for Education and Research in Therapeutics (CERTs) Vice-Chair of Steering Committee 2007 - 2009 Canadian Heart Research Center Advisory Board 2002 - 2003 Fellow of the European Society of Cardiology 2002 - Medicare Coverage Advisory Committee 2002 - 2003 Institute of Medicine, Clinical Research Roundtable 2003 - 2005 Institute of Medicine Committee on Assessing the Need for Clinical Trials of Testosterone Replacement Therapy 2003 - 2004 Institute of Medicine Committee on Medication Errors 2004 - 2006 Institute of Medicine Forum, Drug Discovery, Development And Translation 2005 - 2006 Center for Information and Study on Clinical Research Participation Board of Advisors 2004 - National Heart, Lung, and Blood Working Group on Hypertension Trials 2004 - 2006 National Library of Medicine Board of Scientific Counselors 2005 - 2009 National Heart, Lung, and Blood Institute Cardiovascular Disease Executive Planning Committee 2006 - 2007 National Heart, Lung, and Blood Institute Working Group On Clinical Trial Design, Co-Chair 2006 - 2007 National Heart, Lung, and Blood Institute Board of External Experts 2007- National Heart, Lung, and Blood Institute Clinical Guidelines Leadership Group for CV Risk Reduction 2007 - 2008 National Heart, Lung and Blood Institute Chairman, Steering committee of the Warfarin Therapy trial 2008 - National Institute of Health – Board of Scientific Counselors 2008 - 2009 National Institute of Health/National Cancer Institute SPORE In Brain Cancer –Internal Advisory Committee 2008 - National Cancer Institute/National Institute of Health Operational Efficiency Working Group (OEWG) 2008 - CTSA Consortium Oversight Steering Committee - Co-Chair 2007 - 2009 Clinical Trials Transformation Initiative (CTTI) - Co-Chair Public-Private Partnership with FDA 2008 - Institute of Medicine Committee on Qualification of Biomarkers and Surrogate Endpoints in Chronic Disease 2009 - National Institute of Environmental Health Science (NIEHS)/NIH - Member, External Clinical Advisory Council 2009 - 2013 CTSA External Advisory Board Membership Columbia University 2008 - UC Davis 2009 - University of Colorado 2009 - University of Chicago 2009 Clinical Research Forum – Chairman 2010 - 2013 NIH-National Advisory Council on Aging 2010 – 2013 American Orthopaedic Association Institute of Medicine Taskforce On Ethics 2010 HHS – Secretary’s Advisory Council on Human Research Protections (SACHRP) – Subcommittee on Harmonization 2010 - 2011 Society for Clinical and Translational Sciences – Board of Directors 2009 – 2013 Office of the Speaker, NC House of Representatives Comparative Effectiveness Study Committee Advisory Board 2010 - 2011 Journal reviewer: Current American Heart Journal PAGE 3 of 114 ROBERT M. CALIFF American Journal of Cardiology Annals of Internal Medicine Cardiosource Clinical Trials Circulation European Heart Journal Heart Lung and Circulation Journal of the American College of Cardiology Journal of the American Medical Association Journal of Invasive Cardiology Lancet New England Journal of Medicine American Journal of Kidney Disease American Journal of Medicine Archives of Internal Medicine Canadian Journal of Cardiology Chest Journal of Clinical Epidemiology Journal of General Internal Medicine Thrombosis and Hemostasis Health Affairs Editorial boards: Current American Heart Journal Cardiosource Clinical Trials Circulation Clinical Trials, The Journal of the Society for Clinical Trials European Heart Journal Heart Lung and Circulation Science Translational Medicine (Advisory Board) Past American Journal of Cardiology Current Treatment Options in Cardiovascular Diseases Journal of Interventional Cardiology Journal of the American College of Cardiology Consultancy: Health Services Research & Development 1984 - Present Veterans Administration Donald W. Reynolds Foundation Scientific Advisory Panel Cardiovascular Research 1998 Honors and awards: Phi Beta Kappa 1973 Duke University Alpha Omega Alpha 1976 Duke University Medical School President, Senior Class 1978 Duke University Medical School Lange Book Award 1978 PAGE 4 of 114 ROBERT M. CALIFF Duke University Medical School Distinguished Resident Teaching Award 1981 University of California at San Francisco School of Medicine Donald F. Fortin Professor, Cardiology 1995 Distinguished Scientist Award for Clinical Research 2004 American College of Cardiology Master of the American College of Cardiology 2006 2006 Clinical Research Award 2006 American Heart Association Duke Distinguished Alumni Faculty Award 2006 AHA Distinguished Scientist Award 2009 Memberships Current American College of Cardiology American College of Physicians American Medical Association American Society of Clinical Investigation Argentine Society of Cardiology Association of American Physicians Drug Information Association Society for Clinical Epidemiology and Health Care Research American Heart Association Association of University Cardiologists European Society of Cardiology Association of American Physicians American Society of Clinical Investigators Society for Clinical Trials, Inc. Selected Recent Invited Lectures: 1998 Dallas, TX, Baylor University Medical Center Visiting Professor, presentation, “Do We Need Academic Cardiologists?” Birmingham, AL, University of Alabama School of Medicine Visiting Professor 1999 Stanford, CA, Stanford University School
Load more

Recommended publications
  • Artificial Intelligence in Health Care: the Hope, the Hype, the Promise, the Peril
    Artificial Intelligence in Health Care: The Hope, the Hype, the Promise, the Peril Michael Matheny, Sonoo Thadaney Israni, Mahnoor Ahmed, and Danielle Whicher, Editors WASHINGTON, DC NAM.EDU PREPUBLICATION COPY - Uncorrected Proofs NATIONAL ACADEMY OF MEDICINE • 500 Fifth Street, NW • WASHINGTON, DC 20001 NOTICE: This publication has undergone peer review according to procedures established by the National Academy of Medicine (NAM). Publication by the NAM worthy of public attention, but does not constitute endorsement of conclusions and recommendationssignifies that it is the by productthe NAM. of The a carefully views presented considered in processthis publication and is a contributionare those of individual contributors and do not represent formal consensus positions of the authors’ organizations; the NAM; or the National Academies of Sciences, Engineering, and Medicine. Library of Congress Cataloging-in-Publication Data to Come Copyright 2019 by the National Academy of Sciences. All rights reserved. Printed in the United States of America. Suggested citation: Matheny, M., S. Thadaney Israni, M. Ahmed, and D. Whicher, Editors. 2019. Artificial Intelligence in Health Care: The Hope, the Hype, the Promise, the Peril. NAM Special Publication. Washington, DC: National Academy of Medicine. PREPUBLICATION COPY - Uncorrected Proofs “Knowing is not enough; we must apply. Willing is not enough; we must do.” --GOETHE PREPUBLICATION COPY - Uncorrected Proofs ABOUT THE NATIONAL ACADEMY OF MEDICINE The National Academy of Medicine is one of three Academies constituting the Nation- al Academies of Sciences, Engineering, and Medicine (the National Academies). The Na- tional Academies provide independent, objective analysis and advice to the nation and conduct other activities to solve complex problems and inform public policy decisions.
    [Show full text]
  • NHS England Briefed Against Gps
    this week NHS RESERVES page 381 • MESH CLINICS page 382 • LIVERPOOL TESTING page 384 LMCs: NHS England briefed against GPs GP leaders have demanded that NHS chair of the BMA’s General Practitioners The BMA’s Richard Vautrey England and NHS Improvement apologise Committee, writing to the NHS chief said it seemed NHS England and retract any communications that may executive, Simon Stevens, asking for had “intentionally sought have harmed their reputation or incited NHSE/I to “apologise to the profession and to create negative media coverage of primary care” complaints by implying that practices had correct damage that has been done.” not been fully involved in care of patients Vautrey wrote, “Implying within the throughout the covid-19 pandemic. press release that GPs are not providing A motion passed at the annual patients with the appointments they conference of England’s local medical need and ‘reminding’ them that they face committees on 27 November said that ‘enforcement action’ if they do not has much of NHSE/I’s communications with presented NHSE/I as antagonistic and GPs, the press, and the public had been completely out of touch with the profession. “abhorrent and insulting.” The conference It also seems to many GPs that NHSE/I has, called for NHSE/I to recognise general by using this tactic, intentionally sought to LATEST ONLINE practice’s contribution to the management create negative media coverage of primary of the pandemic and the continuation of care services. Test for HIV normal service, “particularly given the “The BMA is now hearing large numbers wherever blood is general practitioners who have died in the of reports from practices receiving taken, recommends course of their duties to the public.” complaints and many staff members being UK independent The motion added that it “deplores verbally abused by the public based on commission the habit” of briefi ng journalists before these unsupported and ill-informed media Declarations of communicating with the profession and its articles.
    [Show full text]
  • Patients First
    04 Patients First PATIENTS FIRST THE CLEVELAND CLINIC 2004 ANNUAL REPORT 1 “Patients First” > On Oct. 1, 2004, The Cleveland Clinic welcomed Delos M. Cosgrove, M.D., as its new Chief Executive Offi cer and President. With the inauguration of Dr. Cosgrove, The Cleveland Clinic has rededicated itself to one of the most sacred principles of medicine: “Patients First.” This prin- ciple declares the primacy of patient care, patient comfort and patient communication in every activity undertaken by The Cleveland Clinic. It affi rms the importance of research and education for their contributions to clinical medicine and the improvement of patient care. At the same time, “Patients First” demands a relentless focus on measurable quality. By setting standards, collecting data and analyzing results, The Cleveland Clinic puts patients fi rst through improved outcomes, better service and by providing a healthier future for all. PATIENTS FIRST THE CLEVELAND CLINIC 2004 ANNUAL REPORT 2 Dear Friends: In 2004, The Cleveland Clinic enjoyed the best year in its and visitor spending. We are currently the largest employer history. We helped more patients and contributed more in Northeast Ohio, and the third largest non-governmental to our local and regional economies than ever before. The employer in the state. Our economic activities create ad- number of patient visits, surgeries and hospital admis- ditional jobs in the community, for a total of 65,000 jobs sions at The Cleveland Clinic and Cleveland Clinic Health overall. We are responsible for direct and indirect state System have surpassed all previous years. Working as a and local taxes totaling $300 million – including one out team, we are building, educating and innovating for the of every 10 tax dollars collected in the city of Cleveland.
    [Show full text]
  • Anatomy and Atrophy of Medical Paternalism Robert F
    Anatomy and Atrophy of Medical Paternalism Robert F. Graboyes and Eric Topol MERCATUS RESEARCH Robert F. Graboyes and Eric Topol, “Anatomy and Atrophy of Medical Paternalism” (Mercatus Research, Mercatus Center at George Mason University, Arlington, VA, 2017). ABSTRACT Since Ancient Greece, a guiding principle of Western medicine has been pater- nalism—the idea that doctors have intrinsically superior insights, patients should defer to their edicts, and this asymmetry is a desirable state of affairs. In the 20th century, new medical knowledge and technologies accumulated at an unprecedented rate, and medical paternalism arguably reached its zenith. Now, however, new technologies are eroding the doctor’s privileged role by deconstructing, digitizing, and democratizing medical knowledge. Digital technologies and other breakthroughs offer unprecedented opportunities to save lives and cut costs. Along with self-interest, however, selective strains of risk aversion, technophobia, and egalitarianism among physicians are gener- ating resistance to the new reality. This article catalogs the motives for and impact of medical paternalism, the reasons for its decline, and potential policy responses that would ease the transition. JEL codes: I11, I13, I18, K2 Keywords: health care, healthcare, medicine, physician, doctors, consumer sov- ereignty, licensure, certification, regulation, prices, technology, digital health The Mercatus Center gratefully acknowledges the financial support of the John Templeton Foundation for research on healthcare policy in the United States. Copyright © 2017 by Robert F. Graboyes, Eric Topol, and the Mercatus Center at George Mason University The views expressed in Mercatus Research are the authors’ and do not represent official positions of the Mercatus Center or George Mason University. Patients .
    [Show full text]
  • Commencement
    UN IVERS IT Y 0 F R 0 CHESTER 0 N E HUN 0 R E 0 SIXTY~ FIRST COMMENCEMENT MAY 2011 Introduction, 4 Honorary Awards, 5 Honor Societies and Awards, 1 0 Doctoral Degree Candidates, 14 Doctor of Philosophy, 14 School of Nursing, 15 Doctor of Nursing Practice, 15 Eastman School of Music_, 16 Doctor of Musical Arts, 16 Doctor of Education, 16 Degree Candidates, 17 School of Arts and Sciences, 1 7 Bachelor of Arts, 17 Bachelor of Science, 22 Master of Arts, 25 Master of Science, 26 Bachelor of Arts, 2 7 Bachelor of Science, 27 Master of Science, 28 Eastman School of Music, 30 Bachelor of Music, 30 Master of Arts, 31 Master of Music, 31 School of Medicine and Dentistry, 32 Master of Arts, 32 M aster of Science, 32 M aster of Public Health, 32 Doctor of M edicine and Doctor of Philosophy, 33 Doctor of M edicine and Doctor of Philosophy with Distinction in Research, 33 Doctor of M edicine with Distinction in Research and with Distinction in Community Service, 33 Doctor of Medicine with Distinction in Research, 33 Doctor of M edicine with Distinction in Community Service, 33 Doctor of M edicine, 33 William E. Simon <L;raduate School of Business Administration, 34 School of Nursing, 35 Bachelor of Science, 35 M aster of Science, 36 M argaret Warner Graduate School of Education and Human Development, 37 M aster of Science, 37 The Genesee, 39 Campus M ap, 40 Jntrodu( lion ARich Tradition at Rochester The commencement season has always stnod out as the of the l:n iversity, and two silver bands are engraved with the "supreme festival" on Rochester 's academic calendar, Arthur names ' >f the Cniversity's presidents.
    [Show full text]
  • Dr Eric Topol ******@***Scripps.Edu Cardiologist and Geneticist, Directs
    Zoom On: Dr. Eric Topol, Translational Science Leader Dr Eric Topol ******@***scripps.edu Cardiologist and Geneticist, Directs - Scripps Translational Science Institute, La Jolla, CA, USA Chief Academic Officer - Scripps Health Eric Topol, MD is a cardiologist and geneticist who directs the Scripps Translational Science Institute (La Jolla, CA, USA). He is also the Chief Academic Officer at Scripps Health, and a senior consultant at the Scripps Clinic’s Division of Cardiovascular Diseases. He is a professor of genomics in the Department of Molecular and Experimental Medicine, where his research focuses on individualised medicine and the interface of genomics and technology. In 2012, Dr. Topol was named the Most Influential Physician Executive in Healthcare by Modern Healthcare for taking on the topic of how big data will revolutionise hospitals and healthcare in general. In his 2012 book The Creative Destruction of Medicine, Dr. Topol addresses the topic of how healthcare stands to benefit from technology and the wireless age. The tools which are increasingly used by physicians and patients alike, such as mobile phones and pocket computers, are not only useful for their ability to connect doctors and patients. The greatest potential exists in their generation of health information that will serve researchers in ways that data from clinical trials cannot. Population-based studies are limited in the ways they can predict how patients respond to disease therapies, but personalised medicine that ultimately includes genomic sequencing and printing technology will change the way patients are diagnosed and treated. Dr. Topol has been elected to the National Academy of Sciences’ Institute of Medicine, and has received numerous awards including the European Society of Cardiology’s Andreas Gruntzig Award and the Thompson Scientific Award “Doctor of the Decade”.
    [Show full text]
  • D I V I S I O Ns, D E Pa R T M E N T S, I N S T I T U T Es, and Centers
    section four D I V I S I O N S, D E PA R T M E N T S, I N S T I T U T E S, AND CENTERS 1 5 5 11. DIVISION OF MEDICINE BY MUZAFFAR AHMAD, CLAUDIA D’ARCANGELO, AND JOHN CLOUGH A good physician knows his patient through and through, and his knowledge is bought dearly. Time, sympathy, and understanding must be lavishly dispensed, but the reward is to be found in that personal bond, which forms the greatest satisfaction of medical practice. —A.C. Ernstene B E G I N N I N G S THE DIV I S I O N OF MED I C I N E HA S PL AY E D AN IM P O R TAN T RO L E IN TH E development of medical practice at The Cleveland Clinic since its opening in 1921. Dr. John Phillips, the only internist among the four founders, was the first chief of the Division of Medicine, then called the Medical Department. He was a true family physician who saw medicine begin to move away from house calls and toward an of fice-based practice during the eight years between 1921 and his untimely death in 1929 at age 50. Nevertheless, he continued to tr eat patients with diverse disorders and make house calls, often spending his entire weekend visiting patients in their homes. Despite his own inclination and experience, Phillips rec o g n i z e d the value of specialization. In 1921, he assigned Henry J.
    [Show full text]
  • PCP MEETING SUMMARY, June 2014
    MEETING SUMMARY PRESIDENT’S CANCER PANEL CANCER COMMUNICATION IN THE DIGITAL ERA: OPPORTUNITIES AND CHALLENGES June 13, 2014 San Diego, California This workshop was the first in the President’s Cancer Panel’s (the Panel) 2014-2015 series, Cancer Communications in the Digital Era: Opportunities and Challenges. During this workshop, representatives from the academic research community, government agencies, advocacy organizations, and nonprofit organizations convened to discuss ways to organize a series of meetings focused on the potential of new media, especially social and participative media technologies, to improve the control of cancer. Participants were encouraged to live-tweet at #NewComm4Cancer during the workshop. President’s Cancer Panel Barbara Rimer, Dr.P.H., Chair Owen Witte, M.D. National Cancer Institute, National Institutes of Health Abby Sandler, Ph.D., Executive Secretary, President’s Cancer Panel Meeting Co-Chair Bradford W. Hesse, Ph.D., Chief, Health Communication and Informatics Research Branch, Division of Cancer Control and Population Sciences, National Cancer Institute Participants David B. Abrams, Ph.D., Executive Director, The Schroeder Institute for Tobacco Research and Policy Studies, Legacy David K. Ahern, Ph.D., Special Advisor, Health Communications and Informatics Research Branch, Division of Cancer Control and Population Sciences, National Cancer Institute Nelvis Castro, B.S., Acting Director, Office of Communications and Education, National Cancer Institute Wen-ying Sylvia Chou, Ph.D., M.P.H., Program Director, Division of Cancer Control and Population Sciences, National Cancer Institute Robert Croyle, Ph.D., Director, Division of Cancer Control and Population Sciences, National Cancer Institute Robert D. Furberg, Ph.D., M.B.A., Senior Clinical Informaticist, RTI International Peter Garrett, A.B., Senior Advisor to the Director, National Cancer Institute Karen Glanz, Ph.D., M.P.H., George A.
    [Show full text]
  • Pmconfprog1 (Page 1)
    Personalized Medicine: Promises and Prospects A Conference Hosted By HARVARD MEDICAL SCHOOL – PARTNERS HEALTHCARE CENTER FOR GENETICS AND GENOMICS November 3-4, 2005 The Conference Center Harvard Medical School Boston, Massachusetts Conference Program November 3, 2005 Dear Colleague, It is my pleasure to welcome you to Personalized Medicine: Promises and Prospects. The past few years have witnessed a revolution in the understanding of health and dis- ease, brought on by the sequencing of the human genome and the creation of a map of human genetic variation. It is now becoming possible to translate this knowledge to patient care. The ability to use genetic and genomic information in diagnosis, prognosis and treatment has been given a name: personalized medicine. The goal of personalized medicine is to provide the right diagnosis and treatment to the right patient at the right time at the right cost. Hosted by the Harvard Medical School – Partners Healthcare Center for Genetics and Genomics (HPCGG) the conference will focus on the perspectives of Government, Pharmaceutical, Academic, and Diagnostic leaders as well as those of healthcare providers and payers in implementing the new paradigm of personalized medicine. The program will feature several personalized medicine case studies on topics such as lung cancer and cardiovascular disease and will highlight the information technology infra- structure needed to make personalized medicine a reality. The tone for the conference will be one that will explore what happens "on the ground" when personalized medicine is put into practice, and what that means for caregivers, patients and payers, as well as for the industries that develop products for personalized medicine.
    [Show full text]
  • Drug Research and Development for Adults Across the Older Age Span the Era of COVID-19 and Beyond the National Academies of Scie
    Hier “rcpe ppt header Large 01.emf” platzieren Drug Research and Development for Adults Across the Older Age Span The Era of COVID-19 and Beyond The National Academies of Sciences, Engineering and Medicine Sven Stegemann Professor for Patient Centric Drug Development and Manufacturing Graz University of Technology K1 Competence Center - Initiated by the Federal Ministry of Transport, Innovation and Technology (BMVIT) and the Federal Ministry of Science, Research and Economy (BMWFW). Funded by the Austrian Research Promotion Agency (FFG), Land Steiermark and the Styrian Business Promotion Agency (SFG). The context of drug development and healthcare technology Covid-19 Quality, Safety and efficacy Special patient populations Policies and Regulations Development Clinical trials Scientificand clinical (incl PFDD) (incl pediatrics & geriatrics) Healthcareprovision evidence Discovery Dev. & clinical trail Patients & Fast track, break through & orphan Technology New modalities Innovation (CAR-T cells) (wearable diagnostics, Digital health programs telemed) Use & generate scientific and clinical evidence directly to patients e.g. Remdesivir, SARS-CoV2 vaccine, digital healthcare, new clinical trials design,... Agenda – August 6, 2020 – 12.00 pm – 1.30 pm Opening remarks by panel moderator, European perspective SVEN STEGEMANN Lessons learned from COVID-19 (12.00 – 1.00 pm) U.S. regulatory changes Digitization of medicine HARPREET SINGH ERIC TOPOL Division Director (Acting) Founder and Director U.S. Food and Drug Administration, Division of Oncology 2 Scripps Research Translational Institute Infectious disease perspective Patient perspective JOHN POWERS BEVERLY CANIN Senior Medical Scientist Patient Advocate Leidos Biomedical Research Cancer and Aging Research Group Telehealth / Physician perspective ERIKA RAMSDALE Panel discussion (1.00 – 1.30 pm) Assistant Professor University of Rochester Medical Center.
    [Show full text]
  • COVID-19 Variants Update Background
    COVID-19 Variants Update Background: I have been writing about COVID-19 since late December 2019, before it even had a name. Many times, the information in the articles was just that, informational – something we, at FirstWatch, thought you should know. Other times, I/we thought it was more critical, more crucial, that you really "got" the information. We shared information from others, again viewed as critical, as you prepared for your personal and/or professional response to this new viral disease. FirstWatch has done that with the utmost care to remain true to the science available on the subject as well as the principles of infection prevention & control, while also considering our mostly First Responder audience and what we know about that large group. Specifically, that First Responders literally respond into the thick of it, without a lot of intel, except what the PSAP Operators and Dispatchers have been able to determine and share. EMS and other First Responders who provide assistance to anyone who has a medical problem, even if they don't know it yet, and even if it's not part of the reason you are there, puts you in a position of risk not seen in hospitals and other medical facilities. That's why we sometimes recommended more diligence, such as assuming everyone may be sick, until you have assessed the situation fully. The atmosphere you may go into may be charged with germs in droplets, aerosols, and on hard & soft surfaces and require more protective PPE, disinfection, and caution. We identified COVID-19 as being transmitted by aerosols over a year before the WHO and CDC formally did.
    [Show full text]
  • Workshop on Jumpstarting Access to Clinical Data for COVID-19 Research Moderators, Panelists, Speakers & Researchers
    Workshop on Jumpstarting Access to Clinical Data for COVID-19 Research Moderators, Panelists, Speakers & Researchers Contents Opening Remarks .......................................................................................................................................... 2 Keynote on COVID-19 ................................................................................................................................... 3 Background ................................................................................................................................................... 4 Acquiring and Linking Data from Different Clinical Environments ............................................................... 5 Creating and Using Platforms ....................................................................................................................... 7 Generalizability, Reproducibility, & Validity ............................................................................................... 10 Things to Consider: Governance, IRB, DACs, Eligibility, and Security Confidentiality ................................ 13 Considering Issues of Diversity and Representativeness ............................................................................ 18 Finalize, Vision and Next Steps ................................................................................................................... 21 Use Cases ...................................................................................................................................................
    [Show full text]